Abstract Number: PB2078
Meeting: ISTH 2020 Congress
Background: Edoxaban is a well-established treatment for the prevention of stroke in NVAF and Systemic Embolism. The older people (>75 y-o) represent a growing group, and have a high risk of complications. The FDA considered that, in patients with AF and a Creatinine Clearance > 95 ml/min, the use of edoxaban is not recommended.
Aims: Primary Objective: To evaluate the efficacy and safety of Edoxaban.
Secondary Objectives: To study the subpopulation of older people (> 75 y-o). To study the subpopulation of hyper-filters.
Methods: This is a descriptive study. A total of 672 patients with NVAF (97%) and DVT (3%) were included. The mean follow-up was 21 months with a median of 23 months. 47.9% women and 52.1% men. The mean age was 75 y-o, being 58.2% over 75 y-o. 16% of patients were hyper-filters. Mean CHA2DS2-VASc was 3.65. Mean HAS-BLED was 3.01.
Results: 0.5% of patients presented stroke. 4 patients presented severe bleeding (3 intracranial-bleeding), dying two of them. In older people, the average age was 81.7 y-o. Average CHA2DS2-VASc of 4.2 and average HAS-BLED of 3.19. 88% of deaths occurred in this group. Among hyper-filter patients, only one stroke occurred, representing 0.5% of this population. 35 patients finished the treatment and the anticoagulant treatment was changed in 4.3% of them.
Conclusions: This is a large sample with more than 23 months of follow-up. The good results of Edoxaban in normal clinical practice may be confirmed for general population, the older population and those with a creatinine clearance of more than 95 ml/min. These data reinforce and even improve the data obtained in the ETNA-AF Europe study with a percentage of Stroke/Systemic Embolism of 0.82% and 1.05% of Major Bleeding with 0.23% of Intracranial Bleeding.
To cite this abstract in AMA style:Garcia Ruiz A, Romero Garcia P, Morente Constantin E, Jurado Chacón M. Study of Real Clinical Practice to Evaluate the Efficacy and Safety of Edoxaban in Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation. Differences between Results by Age and Creatinine Clearance Greater than 95 ml/min [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/study-of-real-clinical-practice-to-evaluate-the-efficacy-and-safety-of-edoxaban-in-prevention-of-stroke-in-patients-with-non-valvular-atrial-fibrillation-differences-between-results-by-age-and-creati/. Accessed September 22, 2023.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/study-of-real-clinical-practice-to-evaluate-the-efficacy-and-safety-of-edoxaban-in-prevention-of-stroke-in-patients-with-non-valvular-atrial-fibrillation-differences-between-results-by-age-and-creati/